James Blachly

James Blachly, MD


Make an Appointment


Overall Patient Satisfaction Rating

4.6 out of 5




I’m an oncologist focused on the treatment of patients diagnosed with Hairy Cell, Acute Myeloid, Acute Lymphocytic and Chronic Lymphocytic Leukemia. I’m a member of the Leukemia Research Program at the OSUCCC – James and serve as an assistant professor in Ohio State’s Division of Hematology.

My research interest is in genomics and gene transcription in leukemia and its relevance in experimental therapeutics. My work explores whether and how mutations and transcriptional attributes can be studied in the context of clinical trials to provide prognostic and predictive information relevant to novel anticancer therapies.

I was recently named as one of six recipients of a Young Investigator Award from the National Comprehensive Cancer Network (NCCN) Foundation. I received a six-figure grant for a project titled “Genomic Stratification and Prognostication of Adult Acute Myeloid Leukemia by Combination Mutation Status.”

I love the collaborative spirit at OSUCCC – James, and how we all share the common purpose of providing optimal and effective care and treatment for patients — and the goal of one day living in a world free of cancer.

Education and Background


University of Arkansas College of Medicine

Little Rock, AR


University of Arkansas for Medical Sciences Medical Center

Little Rock, AR



Ohio State University Wexner Medical Center

Columbus, OH

Board Certifications

American Board of Internal Medicine

American Board of Internal Medicine (Subspecialty: Hematology)

American Board of Internal Medicine (Subspecialty: Medicine Oncology)

Academic Department

Department of Internal Medicine

Division of Hematology

Consulting and Related Relationships

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 11/21/2019, Dr. Blachly has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.


Gilead Sciences, Inc.

AbbVie Inc.

Innate Pharma


Patient Satisfaction Review

The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our Patient Satisfaction Survey page

The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.

Overall Ratings (out of 35 reviews)
4.6 out of 5
Kept you informed about your condition and treatment

4.7/ 5

Amount of time spent with you

4.6/ 5

Concern for your questions and issues

4.6/ 5

Skill and knowledge

4.7/ 5

Overall quality of care

4.6/ 5

Patient Comments (3 total comments)

Reviewed: 10/17/2019

Doctor very smart. Knew answers to all questions.

Reviewed: 1/29/2019

Dr. Blachly was awesome. Even though the news he was giving was not good, he was very kind and explained everything very well.

Reviewed: 1/21/2019

more than professional and made me feel like family


Implementation of standardized variant-calling nomenclature in the age of next-generation sequencing: where do we stand?

Eisfeld AK, Blachly JS, Mrózek K, Kohlschmidt J, Walker CJ, de la Chapelle A, Bloomfield CD

Leukemia 33


Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia.

Mitchell SR, Larkin K, Grieselhuber NR, Lai TH, Cannon M, Orwick S, Sharma P, Asemelash Y, Zhang P, Goettl VM, Beaver L, Mims A, Puduvalli VK, Blachly JS, Lehman A, Harrington B, Henderson S, Breitbach JT, Williams KE, Dong S, Baloglu E, Senapedis W, Kirschner K, Sampath D, Lapalombella R, Byrd JC

Blood Adv 3


Clinical Trials | Lead




Related Videos

Meet James Blachly, MD, Hematologist at the OSUCCC – James
What Is a Clinical Trial? – James Blachly, MD
What Is Leukemia? – James Blachly, MD
Back to Find a Doctor Search

Make an Appointment


Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator


Please enter a keyword (i.e. Name, Location) or choose a Cancer Type